Pulmonary Surfactant in Respiratory Syncytial Virus Bronchiolitis: The Role in Pathogenesis and Clinical Implications

Carregando...
Imagem de Miniatura
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
PEDIATRIC PULMONOLOGY, v.46, n.5, p.415-420, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of lower respiratory tract infection, and the most frequent reason for hospitalization among infants throughout the world. In addition to the acute consequences of the disease, RSV bronchiolitis in early childhood is related to further development of recurrent wheezing and asthma. Despite the medical and economic burden of the disease, therapeutic options are limited to supportive measures, and mechanical ventilation in severe cases. Growing evidence suggests an important role of changes in pulmonary surfactant content and composition in the pathogenesis of severe RSV bronchiolitis. Besides the well-known importance of pulmonary surfactant in maintenance of pulmonary homeostasis and lung mechanics, the surfactant proteins SP-A and SP-D are essential components of the pulmonary innate immune system. Deficiencies of such proteins, which develop in severe RSV bronchiolitis, may be related to impairment in viral clearance, and exacerbated inflammatory response. A comprehensive understanding of the role of the pulmonary surfactant in the pathogenesis of the disease may help the development of new treatment strategies. We conducted a review of the literature to analyze the evidences of pulmonary surfactant changes in the pathogenesis of severe RSV bronchiolitis, its relation to the inflammatory and immune response, and the possible role of pulmonary surfactant replacement in the treatment of the disease. Pediatr Pulmonol. 2011; 46:415-420. (c) 2010 Wiley-Liss, Inc.
Palavras-chave
bronchiolitis, respiratory syncytial virus, human, pulmonary surfactants
Referências
  1. Krishnan S, 2004, VIRAL IMMUNOL, V17, P220, DOI 10.1089/0882824041310612
  2. Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840
  3. Kishore U, 2006, MOL IMMUNOL, V43, P1293, DOI 10.1016/j.molimm.2005.08.004
  4. Ghildyal R, 1999, J INFECT DIS, V180, P2009, DOI 10.1086/315134
  5. Haczku A, 2008, J ALLERGY CLIN IMMUN, V122, P861, DOI 10.1016/j.jaci.2008.10.014
  6. Dargaville PA, 1996, ARCH DIS CHILD, V75, P133
  7. LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0
  8. Bernhard W, 2000, AM J RESP CRIT CARE, V162, P1524
  9. El Saleeby CM, 2010, J PEDIATR-US, V156, P409, DOI 10.1016/j.jpeds.2009.09.043
  10. LeVine AM, 2001, J IMMUNOL, V167, P5868
  11. LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC
  12. Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014
  13. van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x
  14. Barr FE, 2000, AM J RESP CELL MOL, V23, P586
  15. Luchetti M, 1998, ACTA ANAESTH SCAND, V42, P805
  16. Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.3.CO;2-N
  17. Kerr MH, 1999, AM J RESP CRIT CARE, V159, P1115
  18. Linke MJ, 2001, J INFECT DIS, V183, P943, DOI 10.1086/319252
  19. LeVine AM, 1996, CRIT CARE MED, V24, P1062, DOI 10.1097/00003246-199606000-00029
  20. Wang EEL, 1996, J PEDIATR-US, V129, P390, DOI 10.1016/S0022-3476(96)70071-9
  21. Null D, 1998, PEDIATRICS, V102, P531
  22. Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528
  23. Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X
  24. Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392
  25. Welliver RC, 2010, CURR MED RES OPIN, V26, P2175, DOI 10.1185/03007995.2010.505126
  26. Harris J, 2003, CELL MICROBIOL, V5, P671, DOI 10.1046/j.1462-5822.2003.00313.x
  27. Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087
  28. LeVine AM, 2000, J IMMUNOL, V165, P3934
  29. LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849
  30. Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092
  31. Bonnet D, 2005, CARDIOL YOUNG, V15, P256, DOI 10.1017/S1047951105000545
  32. Carbonell-Estrany X, 2010, PEDIATRICS, V125, pE35, DOI 10.1542/peds.2008-1036
  33. Chiba H, 2006, RESPIROLOGY, V11, pS2, DOI 10.1111/j.1440-1843.2006.00797.x
  34. Davison Caroline, 2004, Pediatr Crit Care Med, V5, P482, DOI 10.1097/01.PCC.0000128891.54799.67
  35. GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005
  36. Enhorning G, 2008, CHEST, V133, P975, DOI 10.1378/chest.07-2404
  37. Griese M, 2008, PEDIATR ALLERGY IMMU, V19, P639, DOI 10.1111/j.1399-3038.2007.00695.x
  38. Hamm H, 1996, RESP MED, V90, P251, DOI 10.1016/S0954-6111(96)90097-9
  39. Lahti M, 2002, PEDIATR RES, V51, P696, DOI 10.1023/01.PDR.0000015911.65104.93
  40. Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9
  41. LeVine AM, 1998, AM J RESP CELL MOL, V19, P700
  42. Liu P, 2007, J VIROL, V81, P1401, DOI 10.1128/JVI.01740-06
  43. Luchetti M., 2002, Pediatric Critical Care Medicine, V3, P261, DOI 10.1097/00130478-200207000-00011
  44. NAKAMURA M, 2009, P AM THORAC SOC, V6, P322
  45. Ochoa Sangrador C, 2010, AN PEDIAT BARC, V72
  46. Puthothu Beena, 2007, BMC Pulm Med, V7, P6, DOI 10.1186/1471-2466-7-6
  47. Schmidt R, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-55
  48. SIGURS N, 2010, THORAX 0627
  49. Skelton R, 1999, ACTA PAEDIATR, V88, P942, DOI 10.1080/08035259950168414
  50. Tibby SM, 2000, AM J RESP CRIT CARE, V162, P1251
  51. VanSchaik SM, 1997, PEDIATR RES, V42, P169, DOI 10.1203/00006450-199708000-00007
  52. VENKITARAMAN AR, 1991, CHEM PHYS LIPIDS, V57, P49, DOI 10.1016/0009-3084(91)90048-G
  53. VENTRE K, 2007, COCHRANE DATABASE SY, V24
  54. Ventre K, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005150.pub2
  55. Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387
  56. World Health Organization, AC RESP INF